Medisafe Announces the Appointment of Henry Ancona as Board Chairman

Ancona brings extensive expertise leading and advising technology companies to aid Medisafe’s mission to improve the health and lives of people around the world through medication adherence

BOSTON, MA — December 4, 2017. Medisafe, the leading personalized mobile health platform for medication management with four million patient and caregiver registered users globally, announced today the appointment of Henry Ancona as Chairman of the Board. Mr. Ancona has over 30 years of operational leadership building global businesses for both large and small technology companies. As Chairman, Ancona leverages his diverse industry experience and expertise to provide insights on market approach and growth strategies.

“I am delighted to be joining Medisafe’s Board. As the top medication management application in the world, Medisafe improves patients’ lives by enabling them to take their medications when they need to,” said Ancona. “Medisafe also offers a suite of products to pharma, payors and others that boost adherence, help drive meaningful patient engagement, and provide near real-time analytics on patient behavior.”

Mr. Ancona brings a history of strategic and operational success to Medisafe. He serves as board member/chair, and executive advisor to companies in healthcare, B-to-B software and software-enabled B-to-C businesses. He currently serves as Board Chairman at Signiant, and Board member at BlueConic and at Verne Global. Ancona holds an MBA from Harvard Business School and BS and MS degrees from MIT in electrical engineering and computer science.

“We are thrilled to bring Henry onto our team,” said Medisafe CEO Omri Shor. “Henry’s wisdom and deep experience at the intersection of healthcare, technology, corporate governance, consumer interests and company growth will help Medisafe enhance our mission of improving and saving lives through medication adherence and intelligent empowerment.”

You may also like

Protected: Demo by Medisafe Aug 6 025

There is no excerpt because this is a protected post.

..Read More

80% Pharma Price Cuts? A New Era of Performance-Driven Patient Engagement for Agencies

The second half of 2025 brings an increasingly pressurized pharmaceutical landscape marked by potential federal mandates to slash US drug 

..Read More

Transforming Breast Cancer Care: Proven Adherence Gains for Pharma Execs

Summary Breast cancer remains one of the most prevalent malignancies worldwide, with an estimated 287,850 new invasive cases and 43,250 

..Read More

Want to Learn More?

We bring decades of experience to your challenges—and technology and solutions uniquely designed to meet your needs.